文献速递浆细胞疾病造血干细胞移植与细胞治疗

白消安联合美法仑与单用美法仑预处理在多发性骨髓瘤自体造血干细胞移植中的比较:开放标签随机3期试验

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2019-03-22

该随机3期试验纳入205例新诊断多发性骨髓瘤患者,比较白消安联合美法仑与单用美法仑预处理的疗效。白消安联合美法仑组中位无进展生存期为64.7个月,单用美法仑组为43.5个月(HR 0.53,95%CI 0.30-0.91;p=0.022)。作者认为若其他研究证实,白消安联合美法仑可替代单用美法仑作为预处理方案。

要点

  • 白消安联合美法仑组中位无进展生存期64.7个月,单用美法仑组43.5个月(HR 0.53,95%CI 0.30-0.91;p=0.022)。
  • 两组100天内均无治疗相关死亡。
  • 2-3级黏膜炎在白消安联合美法仑组为77/104例(74%),单用美法仑组为14/98例(14%)。

核心结论

  • 作者认为,若其他正在进行的研究证实,白消安联合美法仑可替代单用美法仑作为新诊断骨髓瘤患者自体造血干细胞移植的预处理方案。

研究设计与样本

  • 开放标签随机3期试验,纳入新诊断多发性骨髓瘤、适合细胞移植、年龄≤70岁、至少疾病稳定期的患者,1:1随机分配。
  • 205例患者被评估并随机分配,202例接受治疗并纳入主要分析:白消安联合美法仑组104例,单用美法仑组98例。
  • 白消安联合美法仑组方案:白消安试验剂量32 mg/m2,随后在第-7、-6、-5、-4天根据药代动力学调整剂量以达到目标日AUC 5000 mmol-minute,美法仑70 mg/m2/天在第-2和-1天给药(美法仑总剂量140 mg/m2)。
  • 单用美法仑组方案:美法仑200 mg/m2在第-2天给药。
  • 随机化通过德克萨斯大学MD安德森癌症中心的临床试验执行网站进行;研究注册号NCT01413178。

主要发现

  • 2011年10月12日至2017年3月22日期间,205例患者被评估并随机分配。
  • 自体造血干细胞移植后90天,白消安联合美法仑组104例中102例(98%)达到部分缓解或更好,单用美法仑组98例中95例(97%)达到部分缓解或更好。
  • 白消安联合美法仑组中位随访22.6个月(IQR 15.2-47.1),单用美法仑组中位随访20.2个月(IQR 8.8-46.6)。
  • 中位无进展生存期:白消安联合美法仑组64.7个月(32.9-64.7),单用美法仑组43.5个月(19.9-未估计)(HR 0.53,95%CI 0.30-0.91;p=0.022)。
  • 两组100天内均无治疗相关死亡;2-3级黏膜炎在白消安联合美法仑组为77/104例(74%),单用美法仑组为14/98例(14%)。

关键数值与推荐

  • 中位无进展生存期:白消安联合美法仑组64.7个月(32.9-64.7) vs 单用美法仑组43.5个月(19.9-未估计),HR 0.53(95%CI 0.30-0.91;p=0.022)。
  • 移植后90天部分缓解或更好:白消安联合美法仑组102/104例(98%) vs 单用美法仑组95/98例(97%)。
  • 2-3级黏膜炎:白消安联合美法仑组77/104例(74%) vs 单用美法仑组14/98例(14%)。
  • 100天内治疗相关死亡:两组均为0例。

临床怎么用

  • 作者认为,若其他正在进行的研究证实,白消安联合美法仑可替代单用美法仑作为新诊断骨髓瘤患者自体造血干细胞移植的预处理方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retrospective studies suggest that conditioning therapy with busulfan plus melphalan could result in longer progression-free survival compared with melphalan alone in patients with multiple myeloma undergoing autologous haemopoietic cell transplantation (auto-HCT). We aimed to test this hypothesis in a randomised trial. METHODS: The primary objective of the study was to compare progression-free survival with conditioning of busulfan plus melphalan with melphalan alone in patients with multiple myeloma. Patients with newly diagnosed multiple myeloma who were eligible for cell transplantation, aged 70 years or younger, with at least stable disease, were randomly assigned (1:1) to treatment. Patients received either busulfan plus melphalan, with a test dose of busulfan 32 mg/m2 followed by pharmacokinetically adjusted doses on days -7, -6, -5, and -4 to achieve a target daily area under the curve (AUC) of 5000 mmol-minute and melphalan 70 mg/m2 per day on days -2 and -1 (total melphalan dose 140 mg/m2), or a melphalan dose of 200 mg/m2 on day -2. Randomisation was performed via a Clinical Trial Conduct Website at the University of Texas MD Anderson Cancer Center. The accrual is complete and final results are presented here. The study is registered with ClinicalTrials.gov, number NCT01413178. FINDINGS: Between Oct 12, 2011, and March 22, 2017, 205 patients were assessed for eligibility and randomly assigned to treatment. The primary analysis of progression-free survival was measured in 202 patients who received treatment: 104 patients in the busulfan plus melphalan group and 98 patients in the melphalan alone group. 90 days after auto-HCT, 102 (98%) of 104 patients given busulfan plus melphalan and 95 (97%) of 98 patients given melphalan alone achieved partial response or better. The median follow-up in the busulfan plus melphalan group was 22·6 months (IQR 15·2-47·1) and 20·2 months (IQR 8·8-46·6) in the melphalan alone group. Median progression-free survival was 64·7 months (32·9-64·7) with busulfan plus melphalan versus 43·5 months (19·9-not estimated) with melphalan alone (hazard ratio 0·53 [95% CI 0·30-0·91]; p=0·022). There were no treatment-related deaths by day 100 in either group. Grade 2-3 mucositis was observed in 77 (74%) of 104 patients in the busulfan plus melphalan group versus 14 (14%) of 98 patients in the melphalan alone group. INTERPRETATION: These findings, if confirmed in other ongoing studies, suggest that busulfan plus melphalan could replace melphalan alone as the conditioning regimen for auto-HCT in patients with newly diagnosed myeloma. FUNDING: This study was funded in part by the National Institutes of Health (NIH) through MD Anderson's Cancer Center Support Grant (CA016672).

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Bashir Q, Thall PF, Milton DR, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019. PMID: 30910541. doi:10.1016/S2352-3026(19)30023-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。